US2014045884A1PendingUtilityA1

Treatment methods of cognitive, emotional and mental ailments and disorders

52
Assignee: SCHULTZ JACK WILLIAMPriority: Aug 31, 2004Filed: Oct 18, 2013Published: Feb 13, 2014
Est. expiryAug 31, 2024(expired)· nominal 20-yr term from priority
Inventors:Jack William Schultz
A61K 31/41A61K 31/381A61K 31/47A61K 31/404
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for the treatment of cognitive, emotional and mental ailments using therapeutically effective amounts of compositions including leukotriene receptor antagonists, leukotriene synthesis inhibitors or leukotriene modifiers, zafirlukasts, montelukasts, other members of the family—lukasts, zileutons.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method, comprising administering to a patient suffering from a family of mental, emotional and cognitive ailments a therapeutically effective amount of a composition affecting the ailment for a specified period of time for relief of the ailments. 
     
     
         2 . The method as claimed in  claim 1  wherein the composition is a leukotriene receptor antagonist. 
     
     
         3 . The method as claimed in  claim 1  wherein the composition is a leukotriene synthesis inhibitor. 
     
     
         4 . The method as claimed in  claim 1  wherein the composition is a leukotriene modifier. 
     
     
         5 . The method as claimed in  claim 1  wherein the composition is a montelukast. 
     
     
         6 . The method as claimed in  claim 1  wherein the composition is a zafirlukast. 
     
     
         7 . The method as claimed in  claim 1  wherein the composition is a zileuton. 
     
     
         8 . The method as claimed in  claim 1  wherein the composition is a member of the family—lukast. 
     
     
         9 . The method as claimed in  claim 1  wherein the composition is administered at an initial dosage of about 20-30 mg. 
     
     
         10 . The method as claimed in  claim 9  wherein additional dosages are administered at periodic intervals. 
     
     
         11 . The method as claimed in  claim 9  wherein the additional dosage is about 5 mg. 
     
     
         12 . The method as claimed in  claim 9  wherein the additional dosage is about 10 mg. 
     
     
         13 . The method as claimed in  claim 9  wherein the additional dosage is about 20 mg. 
     
     
         14 . The method as claimed in  claim 9  wherein the periodic interval is about every 2 hours. 
     
     
         15 . The method as claimed in  claim 9  wherein the periodic interval is about every 4 hours. 
     
     
         16 . The method as claimed in  claim 9  wherein the maximum daily dosage is about 40 mg. 
     
     
         17 . The method as claimed in  claim 9  wherein the maximum daily dosage is about 80 mg. 
     
     
         18 . The method as claimed in  claim 1  wherein the ailments result from mild permanent cognitive and short term memory loss. 
     
     
         19 . The method as claimed in  claim 1  wherein the ailments are caused by prolonged exposure to levels of mold and fungi. 
     
     
         20 . The method as claimed in  claim 14  wherein the mold is  Stachybotrus.    
     
     
         21 . The method as claimed in  claim 1  wherein the ailments can be related to prolonged allergies.

Join the waitlist — get patent alerts

Track US2014045884A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.